Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Serum IL6 as a Prognostic Biomarker and IL6R as a Therapeutic Target in Biliary Tract Cancers

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The Number of Signaling Pathways Altered by Driver Mutations in Chronic Lymphocytic Leukemia Impacts Disease Outcome

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Clonotypic Diversity of the T-cell Receptor Corroborates the Immature Precursor Origin of Cutaneous T-cell Lymphoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Changes in primary and secondary hemostasis in patients with CLL treated with venetoclax and ibrutinib

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Real-World Outcomes for 205 Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Persistent COVID-19 in an Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir Therapy

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Aliki Xochelli
  • Panagiotis Baliakas
  • Ioannis Kavakiotis
  • Andreas Agathangelidis
  • Lesley-Ann Sutton
  • Eva Minga
  • Stavroula Ntoufa
  • Eugen Tausch
  • Xiao-Jie Yan
  • Tait Shanafelt
  • Karla Plevova
  • Myriam Boudjogra
  • Davide Rossi
  • Zadie Davis
  • Alba Navarro
  • Yorick Sandberg
  • Fie Juhl Vojdeman
  • Lydia Scarfò
  • Niki Stavroyianni
  • Andrey Sudarikov
  • Silvio Veronese
  • Tatiana Tzenou
  • Teodora Karan-Djurasevic
  • Mark Catherwood
  • Dirk Kienle
  • Maria Chatzouli
  • Monica Facco
  • Jasmin Bahlo
  • Christiane Pott
  • Lone Bredo Pedersen
  • Larry Mansouri
  • Karin E Smedby
  • Charles C Chu
  • Veronique Giudicelli
  • Marie-Paule Lefranc
  • Panagiotis Panagiotidis
  • Gunnar Juliusson
  • Achilles Anagnostopoulos
  • Ioannis Vlahavas
  • Darko Antic
  • Livio Trentin
  • Marco Montillo
  • Carsten Niemann
  • Hartmut Döhner
  • Anton W Langerak
  • Sarka Pospisilova
  • Michael Hallek
  • Elias Campo
  • Nicholas Chiorazzi
  • Nikos Maglaveras
  • David Graham Oscier
  • Gianluca Gaidano
  • Diane F Jelinek
  • Stephan Stilgenbauer
  • Ioanna Chouvarda
  • Nikos Darzentas
  • Chrysoula Belessi
  • Frederic Davi
  • Anastasia Hadzidimitriou
  • Richard Rosenquist
  • Paolo Ghia
  • Kostas Stamatopoulos
View graph of relations

Purpose: We sought to investigate whether B cell receptor immunoglobulin (BcR IG) stereotypy is associated with particular clinicobiological features among chronic lymphocytic leukemia (CLL) patients expressing mutated BcR IG (M-CLL) encoded by the IGHV4-34 gene, and also ascertain whether these associations could refine prognostication.Experimental Design: In a series of 19,907 CLL cases with available immunogenetic information, we identified 339 IGHV4-34-expressing cases assigned to one of the four largest stereotyped M-CLL subsets, namely subsets #4, #16, #29 and #201, and investigated in detail their clinicobiological characteristics and disease outcomes.Results: We identified shared and subset-specific patterns of somatic hypermutation (SHM) among patients assigned to these subsets. The greatest similarity was observed between subsets #4 and #16, both including IgG-switched cases (IgG-CLL). In contrast, the least similarity was detected between subsets #16 and #201, the latter concerning IgM/D-expressing CLL. Significant differences between subsets also involved disease stage at diagnosis and the presence of specific genomic aberrations. IgG subsets #4 and #16 emerged as particularly indolent with a significantly (P < 0.05) longer time-to-first-treatment (TTFT; median TTFT: not yet reached) compared with the IgM/D subsets #29 and #201 (median TTFT: 11 and 12 years, respectively).Conclusions: Our findings support the notion that BcR IG stereotypy further refines prognostication in CLL, superseding the immunogenetic distinction based solely on SHM load. In addition, the observed distinct genetic aberration landscapes and clinical heterogeneity suggest that not all M-CLL cases are equal, prompting further research into the underlying biological background with the ultimate aim of tailored patient management. Clin Cancer Res; 1-10. ©2017 AACR.

Original languageEnglish
JournalClinical Cancer Research
Volume23
Issue number17
Pages (from-to)5292-5301
ISSN1078-0432
DOIs
Publication statusPublished - Sep 2017

    Research areas

  • Journal Article

ID: 51608059